Effects of polymorphisms of theSLCO2B1transporter gene on the pharmacokinetics of montelukast in humans

SLCO2B1 genetic polymorphisms in a Korean population: pyrosequencing analyses and comprehensive comparison with other populations

(2013) Kyoung-Ah Kim et al.   MOLECULAR BIOLOGY REPORTS

SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren

(2012) Tuija Tapaninen et al.   Pharmacogenetics and Genomics

Oral drug delivery utilizing intestinal OATP transporters

(2011) Ikumi Tamai   ADVANCED DRUG DELIVERY REVIEWS

Genetic Polymorphisms of OATP Transporters and Their Impact on Intestinal Absorption and Hepatic Disposition of Drugs

(2011) Takeo Nakanishi et al.   Drug Metabolism and Pharmacokinetics

Microdosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1), and Interaction (Grapefruit Juice) Profiles of Celiprolol Following the Oral Microdose and Therapeutic Dose

(2011) Ichiro Ieiri et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren

(2010) Tuija Tapaninen et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effect of Citrus Juice andSLCO2B1Genotype on the Pharmacokinetics of Montelukast

(2010) E. B. Mougey et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans

(2010) Junko Imanaga et al.   Pharmacogenetics and Genomics

Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers

(2010) Yumiko Akamine et al.   XENOBIOTICA

Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response

(2009) Edward B. Mougey et al.   Pharmacogenetics and Genomics

Impact of regulatory polymorphisms in organic anion transporter genes in the human liver

(2009) Masayo Aoki et al.   Pharmacogenetics and Genomics